Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 1, 2004

Primary Completion Date

October 1, 2008

Study Completion Date

October 1, 2008

Conditions
Breast Cancer
Interventions
DRUG

Albumin-bound paclitaxel

Administered by intravenous infusion.

DRUG

Carboplatin

Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.

DRUG

Herceptin®

Administered by IV infusion

Trial Locations (14)

2007

Lombardi Cancer Center Georgetown University Hospital, Washington D.C.

10021

Memorial Sloan-Kettering Cancer Center, New York

15213

University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh

20010

Washington Hospital Center, Washington D.C.

30341

Gerogia Cancer Specialist, Atlanta

33401

Palm Beach Cancer Institute, West Palm Beach

33705

Gulf Coast Oncology Associates, St. Petersburg

34667

Florida Cancer Institute, Hudson

78705

Southwest Regional Cancer Center, Austin

90806

Breastlink Med Group, Long Beach

98104

Swedish Medical Center Cancer Institute Research, Seattle

06902

Hematology/Oncology P.C. Carl & Dorothy Bennet Cancer Center, Stamford

04074

Maine Center for Cancer Medicine and Blood Disorders, Scarborough

02903

Rhode Island Hospital, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY